Universitat de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (18)

2023

  1. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial

    European Journal of Heart Failure, Vol. 25, Núm. 11, pp. 2007-2017

  2. β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial

    European Journal of Heart Failure, Vol. 25, Núm. 3, pp. 373-385

2021

  1. Consensus on improving the comprehensive care of patients with acute heart failure

    Revista Clinica Espanola, Vol. 221, Núm. 3, pp. 163-168

  2. Reply to G. Betts’s letter referring to “Serum potassium dynamics during acute heart failure hospitalization”

    Clinical Research in Cardiology

2020

  1. Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain

    Journal of Medical Economics, Vol. 23, Núm. 12, pp. 1418-1424

  2. Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial

    JACC: Basic to Translational Science, Vol. 5, Núm. 4, pp. 317-327

  3. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain

    Revista Espanola de Cardiologia, Vol. 73, Núm. 5, pp. 361-367

  4. Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use

    Journal of cardiovascular pharmacology, Vol. 76, Núm. 1, pp. 4-22

  5. Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use

    Cardiac Failure Review, Vol. 6

2019

  1. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period

    ESC Heart Failure, Vol. 6, Núm. 1, pp. 174-181

2016

  1. Consenso para la mejora de la atención integral de los pacientes con insuficiencia cardíaca aguda: versión resumida

    Revista Clinica Espanola, Vol. 216, Núm. 5, pp. 260-270

  2. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients

    Transplant Infectious Disease, Vol. 18, Núm. 6, pp. 819-831

2015

  1. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey

    Clinical Microbiology and Infection, Vol. 21, Núm. 6, pp. 604.e1-604.e9

2013

  1. Executive summary. Management of influenza infection in solid-organ transplantrecipients: Consensus statement of the Group for the Study of Infection In Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases Andclinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 8, pp. 528-534

  2. Management of influenza infection in solid-organ transplant recipients:consensus statement of the group for the study of infection in transplantrecipients (GESITRA) of the spanish society of infectious diseases and clinicalmicrobiology (SEIMC) and the spanish network for research in infectiousdiseases (REIPI)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 8, pp. 526.e1-526.e20

2011

  1. Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: Practical clinical management questions

    Clinical Transplantation, Vol. 25, Núm. 5

2010

  1. Temporal trends in the use of proliferation signal inhibitors in maintenance heart transplantation: A Spanish multicenter study

    Transplantation Proceedings, Vol. 42, Núm. 8, pp. 2997-3000

2003

  1. Morphological and morphometric assessment of the encephalic ventricles using different neuroimaging techniques

    European Journal of Anatomy, Vol. 7, Núm. 1, pp. 35-57